UBS Group
KTTA icon

UBS Group’s Pasithea Therapeutics KTTA Stock Holding History

UBS Group’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$35 Sell
71
-188,040
-100% -$94.6K ﹤0.01% 10968
2026
Q2 		$96.9K Buy
188,111
+161,962
+619% +$111K ﹤0.01% 7211
2026
Q1 		$19.4K Buy
26,149
+12,886
+97% +$10.8K ﹤0.01% 7958
2025
Q4 		$17.1K Sell
13,263
-5,118
-28% -$4.5K ﹤0.01% 7895
2025
Q3 		$13.5K Sell
18,381
-23,761
-56% -$17.4K ﹤0.01% 8397
2025
Q2 		$30.4K Buy
42,142
+37,805
+872% +$41.3K ﹤0.01% 8151
2025
Q1 		$5.64K Sell
4,337
-8,531
-66% -$15.1K ﹤0.01% 8970
2024
Q4 		$40.5K Buy
12,868
+6,301
+96% +$22.3K ﹤0.01% 7430
2024
Q3 		$35.6K Buy
6,567
+6,529
+17,182% +$32.2K ﹤0.01% 7039
2024
Q2 		$192 Sell
38
-570
-94% -$3.72K ﹤0.01% 9082
2024
Q1 		$4.41K Buy
+608
New +$4.32K ﹤0.01% 7628
2023
Q4 		– Sell
-4
Closed -$40 – 9627
2023
Q3 		$40 Sell
4
-342
-99% -$3.74K ﹤0.01% 9041
2023
Q2 		$3.39K Buy
+346
New +$2.79K ﹤0.01% 7637
2023
Q1 		– Sell
-637
Closed -$8.15K – 9999
2022
Q4 		$8.15K Buy
637
+364
+133% +$7.27K ﹤0.01% 8812
2022
Q3 		$7K Sell
273
-367
-57% -$8.62K ﹤0.01% 8879
2022
Q2 		$13K Buy
+640
New +$13.6K ﹤0.01% 7517
2021
Q4 		– Sell
-165
Closed -$10K – 10491
2021
Q3 		$10K Buy
+165
New +$10K ﹤0.01% 8003

Other funds holding KTTA

AdvisorShares Investments
AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Hurley Capital
Hurley Capital New York $206M AUM 18.12% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

UBS Group's KTTA Position: Q3 2026 in Review

UBS Group reduced its Pasithea Therapeutics (KTTA) stake by 100% in Q3 2026, selling an estimated $94.6K and leaving 71 shares worth $35. The position accounts for ﹤0.01% of the portfolio, ranked #10968.

UBS Group first reported a position in KTTA in Q3 2021 and has held it in 17 quarters since. The position peaked at $96.9K in Q2 2026. 6 funds tracked by Wall St. Rank hold KTTA as of Q3 2026.

  • UBS Group held 71 shares of Pasithea Therapeutics worth $35 as of Q3 2026.
  • UBS Group sold 188,040 Pasithea Therapeutics shares in Q3 2026, an estimated $94.6K.
  • Pasithea Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10968 holding.
  • UBS Group first reported a position in Pasithea Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • UBS Group's Pasithea Therapeutics position peaked at $96.9K in Q2 2026.
  • 6 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.